microRNA Biomarkers as Potential Diagnostic Markers for Cancer - Genomic Biomarkers for Pharmaceutical Development - page 123

[209] Ding X, Ding J, Ning J, Yi F, Chen J, Zhao D, et al. Circulating microRNA-122 as a potential biomarker for
liver injury. Mol Med Report 2012;5:1428-32.
[210] Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carci-
noma. J Clin Gastroenterol 2011;45:355-60.
[211] Tomimaru Y, Eguchi H, Nagano H, Wada H, Kobayashi S, Marubashi S, et al. Circulating microRNA-21 as a
novel biomarker for hepatocellular carcinoma. J Hepatol 2012;56:167-75.
[212] Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic
hepatitis C and non-alcoholic fatty liver disease. PLoS One 2011;6:e23937.
[213] Ferro M, Bruzzese D, Perdona S, Mazzarella C, Marino A, Sorrentino A, et al. Predicting prostate biopsy out-
come: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. Clin Chim
Acta 2012;413:1274-8.
[214] Ramos CG, Valdevenito R, Vergara I, Anabalon P, Sanchez C, Fulla J. PCA3 sensitivity and specificity for
prostate cancer detection in patients with abnormal PSA and / or suspicious digital rectal examination. First
Latin American experience. Urol Oncol 2012; <http://dx.doi.org/10.1016/j.urolonc.2012.05.002> .
[215] Hassan O, Ahmad A, Sethi S, Sarkar FH. Recent updates on the role of microRNAs in prostate cancer.
J Hematol Oncol 2012;5:9.
[216] Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Muller SC, Ellinger J. Circulating microRNAs
(miRNA) in serum of patients with prostate cancer. Urology 2011;77: 1265, e9-16.
[217] Selth LA, Townley S, Gillis JL, Ochnik AM, Murti K, Macfarlane RJ, et al. Discovery of circulating microRNAs
associated with human prostate cancer using a mouse model of disease. Int J Cancer 2012;131:652-61.
[218] Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, et al. Changes in circulating microRNA
levels associated with prostate cancer. Br J Cancer 2012;106:768-74.
[219] Gonzales JC, Fink LM, Goodman Jr. OB, Symanowski JT, Vogelzang NJ, Ward DC. Comparison of circulating
MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-speciic antigen for determin-
ing treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer 2011;9:39-45.
[220] Nguyen HC, Xie W, Yang M, Hsieh CL, Drouin S, Lee GS, et al. Expression differences of circulating micro-
RNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate 2013
Mar;73(4):346-54.
[221] Shen J, Hruby GW, McKiernan JM, Gurvich I, Lipsky MJ, Benson MC, et al. Dysregulation of circulating
microRNAs and prediction of aggressive prostate cancer. Prostate 2012;72:1469-77.
[222] Kim YK, Yeo J, Ha M, Kim B, Kim VN. Cell adhesion-dependent control of microRNA decay. Mol Cell
2011;43:1005-14.